Research has shown that a low level of extracorporeal cardiac shock wave therapy (ECSWT) can upregulate VEGF, a potent mitogen that triggers angiogenesis in human umbilical vascular endothelial cells to ameliorate myocardial ischemia and refractory angina pectoris.3 Here, VEGFA is linked to myocardial ischemia.